Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00035334 · ClinicalTrials.gov registry record · Phase 2
Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis
A Phase 2 study, sponsored by Bellus Health Inc. - a GSK company.
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
NCT00035334: Completed Phase 2 study, sponsored by Bellus Health Inc. - a GSK company.
NCT00035334 is a Phase 2 study that has completed, run by Bellus Health Inc. - a GSK company. The registered enrollment target is 150 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (13% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00035334, a Phase 2 study, has completed, sponsored by Bellus Health Inc. - a GSK company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
Study Summary
The main objective of this study is to evaluate the safety and efficacy of NC-503 compared to placebo in patients with secondary (AA) amyloidosis using a composite assessment of clinical improvement/worsening of both renal and gastrointestinal functions.
Interventions
- DRUG NC-503 (Anti-amyloidotic (AA) Agent)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2001-10 |
| Est. Completion | 2004-12 |
| Phase | Phase 2 |
What the finished NCT00035334 record still lists
NCT00035334 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (13% higher).
The record links to 0 conditions, and to 1 intervention - of which NC-503 (Anti-amyloidotic (AA) Agent) is the first listed.
NCT00035334 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00035334 about?
NCT00035334 is a clinical study titled "Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis". The main objective of this study is to evaluate the safety and efficacy of NC-503 compared to placebo in patients with secondary (AA) amyloidosis using a composite assessment of clinical improvement/worsening of both renal and gastrointestinal functions.
What is the current status of trial NCT00035334?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2001-10. Estimated completion is 2004-12.
What interventions are being tested in trial NCT00035334?
The interventions under investigation include: NC-503 (Anti-amyloidotic (AA) Agent) (DRUG).
Who is sponsoring clinical trial NCT00035334?
This trial is sponsored by Bellus Health Inc. - a GSK company, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00035334's enrollment target sits among peer trials
150 455th of 2000 higher than 1,510 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia